Soligenix buys an orphan cancer candidate; Texas biotech backer banks $40M;

@FierceBiotech: EuroBiotech Report: AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015, more. More | Follow @FierceBiotech

@JohnCFierce: ICYMI - Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. Report | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce

> Former SAC Capital Advisors trader Mathew Martoma, convicted of making millions in biotech's largest insider trading scheme, lost a bid to toss out his guilty verdict, setting him up for sentencing next week. News

> Soligenix paid an undisclosed sum for SGX301, a Phase III-ready treatment for an orphan form of lymphoma. More

> San Antonio biotech investor Targeted Technology has put together a $40 million fund to back emerging life sciences companies. Story

Medical Device News

@FierceMedDev: Myriad's multigene predictive cancer test shows utility in new trial. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery article | Follow @MichaelGFierce

@EmilyWFierce: Case hedges bets on brain device developer with a smartphone-based system for traumatic brain injuries. More from Bloomberg | Follow @EmilyWFierce

> Israeli colon capsule maker bucks M&A trend with plans for $60M IPO. News

> Researchers diagnose atrial fibrillation via webcam. Story

Pharma News

@FiercePharma: Top-read in FiercePharmaManufacturing Thursday: $ACT production not meeting demand for new version of Alzheimer's drug. Article | Follow @FiercePharma

@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. More | Follow @EricPFierce

@CarlyHFierce: Legendary Genentech CEO Levinson cuts last ties with Roche. Story | Follow @CarlyHFierce

> Merck's melanoma 'game-changer' Keytruda likely to bolster drug pricing debate. Article

> Feds intercept pharmacist linked to meningitis outbreak as he headed to Hong Kong. Story

Suggested Articles

Pandion will test its lead program in patients with refractory ulcerative colitis and move a second program into phase 1.

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.